Øivind Torkildsen
Øivind Torkildsen
Verified email at
Cited by
Cited by
Disease‐modifying treatments for multiple sclerosis–a review of approved medications
Ø Torkildsen, KM Myhr, L Bø
European journal of neurology 23, 18-27, 2016
The cuprizone model for demyelination
Ø Torkildsen, LA Brunborg, KM Myhr, L Bø
Acta Neurologica Scandinavica 117, 72-76, 2008
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ...
Multiple Sclerosis Journal 21 (8), 1013-1024, 2015
Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation
Y Xiao, J Jin, M Chang, JH Chang, H Hu, X Zhou, GC Brittain, ...
Nature medicine 19 (5), 595-602, 2013
Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation
A Lossius, JN Johansen, Ø Torkildsen, F Vartdal, T Holmøy
Viruses 4 (12), 3701-3730, 2012
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial
Ø Torkildsen, S Wergeland, S Bakke, AG Beiske, KS Bjerve, H Hovdal, ...
Archives of neurology 69 (8), 1044-1051, 2012
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment
KI Løken-Amsrud, T Holmøy, SJ Bakke, AG Beiske, KS Bjerve, ...
Neurology 79 (3), 267-273, 2012
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
G Disanto, R Adiutori, R Dobson, V Martinelli, G Dalla Costa, T Runia, ...
Journal of Neurology, Neurosurgery & Psychiatry 87 (2), 126-129, 2016
Neurofilament light chain predicts disease activity in relapsing-remitting MS
KN Varhaug, C Barro, K Bjørnevik, KM Myhr, Ø Torkildsen, S Wergeland, ...
Neurology-Neuroimmunology Neuroinflammation 5 (1), 2018
Dietary vitamin D3 supplements reduce demyelination in the cuprizone model
S Wergeland, Ø Torkildsen, KM Myhr, L Aksnes, SJ Mørk, L Bø
PloS one 6 (10), e26262, 2011
Neurofilament light chain as a biomarker in multiple sclerosis
KN Varhaug, Ø Torkildsen, KM Myhr, CA Vedeler
Frontiers in neurology 10, 338, 2019
Time trends in the incidence and prevalence of multiple sclerosis in N orway during eight decades
N Grytten, Ø Torkildsen, KM Myhr
Acta Neurologica Scandinavica 132, 29-36, 2015
Upregulation of immunoglobulin‐related genes in cortical sections from multiple sclerosis patients
Ø Torkildsen, C Stansberg, SM Angelskår, EJ Kooi, JJG Geurts, ...
Brain Pathology 20 (4), 720-729, 2010
Selective processing of linguistic and pictorial food stimuli in females with anorexia and bulimia nervosa
KM Stormark, Ø Torkildsen
Eating behaviors 5 (1), 27-33, 2004
Glitazone use associated with reduced risk of Parkinson's disease
B Brakedal, I Flønes, SF Reiter, Ø Torkildsen, C Dölle, J Assmus, ...
Movement Disorders 32 (11), 1594-1599, 2017
Vitamin D–dependent rickets as a possible risk factor for multiple sclerosis
Ø Torkildsen, PM Knappskog, HI Nyland, KM Myhr
Archives of neurology 65 (6), 809-811, 2008
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis
S Kvistad, KM Myhr, T Holmøy, S Bakke, AG Beiske, KS Bjerve, H Hovdal, ...
Multiple Sclerosis Journal 20 (14), 1833-1840, 2014
Month of birth as a risk factor for multiple sclerosis: an update
Ø Torkildsen, N Grytten, J Aarseth, KM Myhr, MT Kampman
Acta Neurologica Scandinavica 126, 58-62, 2012
Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model
S Fjær, L Bø, A Lundervold, KM Myhr, T Pavlin, Ø Torkildsen, ...
PLoS One 8 (12), e84162, 2013
Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis
E Røsjø, A Lossius, N Abdelmagid, JC Lindstrøm, MT Kampman, ...
Multiple Sclerosis Journal 23 (3), 395-402, 2017
The system can't perform the operation now. Try again later.
Articles 1–20